This paper concludes that findings suggest that 1) long-term omega-3 fatty acid supplementation may reduce risk of Alzheimer’s disease (AD); 2) dietary omega-3 fatty acid intake, especially DHA, may lower risk of dementia or cognitive decline; and 3) peripheral biomarkers of omega-3 fatty acids may serve as predictors of cognitive decline. However, further investigation is needed to understand the gene–environment interactions involved in the intake of omega-3 fatty acids.
In this review, we discuss how cellular senescence contributes to brain aging and neurodegenerative diseases, and the relationship between protein aggregation and cellular senescence.
This study aimed to investigate the amelioration effects of preventive TEAS treatment (P-TEAS) on cognitive impairment and oxidative stress in AD model rats.
This article explores the potential of Traditional Chinese Medicine (TCM) as a treatment for Alzheimer's disease, highlighting the holistic approach of TCM and its promising results in improving cognitive function in Alzheimer's patients. It emphasizes the need for further rigorous clinical trials to validate these findings.
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
This Comment article supports SDG 3 and 16 by highlighting how complex humanitarian settings have become fertile environments for spreading misinformation, disinformation, and malinformation, and how the 2021 release of the Oxford Statement on International Law Protection in Cyberspace, which touches on sovereignty, incitement, human rights, criminal law, general rules of international humanitarian law, and international criminal law, is an important first step to address this type of disinformation.
Elsevier,
Overcoming Obstacles in Drug Discovery and Development, Surmounting the Insurmountable—Case Studies for Critical Thinking 2023
Racial and ethnic disparities among clinical trial participants is a long-standing issue demanding attention in the research community as advances in precision medicine increase. This exclusion from clinical trial enrollment has tangible consequences, preventing traditionally underserved populations from benefitting from health innovation and cutting-edge technologies. Aggregation of populations into a generalized treatment population lends to the evident healthcare inequities we see today and support SDG3
